Profil bibliographique

Hiromichi Nakajima

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

102Publications signalées

2031Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Congenital Heart Disease StudiesCancer Immunotherapy and BiomarkersPARP inhibition in cancer therapyColorectal Cancer Treatments and StudiesOvarian cancer diagnosis and treatment

Publications récentes

Accès ouvert 2026 articleOpenAlex

Longitudinal ctDNA profiling to guide anti-EGFR rechallenge in metastatic colorectal cancer: a prospective single-arm phase II trial

Yoshinori Kagawa, Daisuke Kotani, Hiroya Taniguchi, Tadayoshi Hashimoto et autres

0 citationsCommunications Medicine

Accès ouvert 2026 articleOpenAlex

cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer

Mika Okazawa‐Sakai, Takao Fujisawa, Tatsuyuki Chiyoda, Hiroshi Yagi et autres

0 citationsJournal of Gynecologic Oncology

Accès ouvert 2026 articleOpenAlex

Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis

Junki Onishi, Suguru Odajima, Masashi Wakabayashi, Yuki Kochi et autres

0 citationsJournal of Gynecologic Oncology

Accès ouvert 2026 articleOpenAlex

Efficacy and Safety of Investigational Treatments in Contemporary Early-Phase Clinical Trials for Japanese Gynecologic Cancers: A Single-Institution Retrospective Analysis

Misao Fukuda, Hiromichi Nakajima, Kenichi Harano, Chikako Funasaka et autres

0 citationsJCO oncology advances.

2026 conference-abstractOpenAlex

Safety and preliminary efficacy of M9466 (HRS-1167) in combination with abiraterone acetate and prednisone/prednisolone (AA-P) in patients (pts) with metastatic prostate cancer in the phase 1 DDRiver 501 study.

V. Boni, Johann S. De Bono, Hiromichi Nakajima, Hiroaki Kikukawa et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report

Nobuyuki Takahashi, Kenichi Harano, Chikako Funasaka, Hiromichi Nakajima et autres

0 citationsFrontiers in Oncology

Accès ouvert 2026 articleOpenAlex

Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma

N. Takahashi, Chikako Funasaka, Mai Shimura, Akira Hirota et autres

0 citationsThe Oncologist

2026 conference-abstractOpenAlex

Abstract 1086: HER2 expression in circulating tumor cells as a minimally invasive biomarker of therapeutic response to trastuzumab deruxutecan in breast cancer

Toru Mukohara, Nobuaki Matsubara, Yusuke Takahashi, Kentaro Shirai et autres

0 citationsCancer Research

2026 conference-abstractOpenAlex

Abstract 1073: Monitoring androgen receptor and neuroendocrine marker expression dynamics in CTCs in patients with mCRPC

Nobuaki Matsubara, Kentaro Shirai, Hiroyuki Obinata, Hiromichi Nakajima et autres

0 citationsCancer Research

Accès ouvert 2026 preprintOpenAlex

Second Androgen Receptor Signaling Inhibitor as a Control Arm in Clinical Trials for Metastatic Castration-Resistant Prostate Cancer: A Single-Center, Retrospective Cohort Study

Mao Uematsu, Hiromichi Nakajima, Chihiro Kondoh, Masashi Wakabayashi et autres

0 citationsSSRN Electronic Journal

Accès ouvert 2025 articleOpenAlex

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study

Yasutoshi Kuboki, Nobuaki Matsubara, Hiromichi Nakajima, Takao Fujisawa et autres

0 citationsInvestigational New Drugs

Accès ouvert 2025 articleOpenAlex

Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study

Miki Hayakawa, Hiromichi Nakajima, Kenichi Harano, Shogo Watanabe et autres

0 citationsGynecologic Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.